Loading...
•
Mar 31, 2024
NextCure Q1 2024 Earnings Report
NextCure reported first quarter 2024 financial results and provided a business update.
Key Takeaways
NextCure reported a net loss of $17.1 million for the first quarter of 2024, with cash, cash equivalents, and marketable securities totaling $96.0 million. The company expects these financial resources to fund operations into the second half of 2026.
Phase 1b data for NC410 in combination with pembrolizumab will be presented at ASCO in June.
Preclinical data from LNCB74 (B7-H4 ADC) was presented at AACR.
Cash of approximately $96.0 million is expected to fund operations into the second half of 2026.
Planned submission of an investigational new drug application for LNCB74 by year-end.